AMD / Netherlands
Market Size
$4.1B
2025 est.
✓ VerifiedCAGR
8.7%
2024–2029
~ EstimatedPatients
~85K
NL treated
✓ VerifiedLeader
Brolucizumab
31% share
~ EstimatedReport Agents
Market Summary
3 sources citedThe Netherlands AMD market is valued at $4.1B (2025), driven by an ageing population and high anti-VEGF adoption. Brolucizumab holds the leading market share at 31%, followed by aflibercept at 28%. Biosimilar entrants are expected to compress pricing from 2026 onward.
Market Intelligence
10 AI agents produce a full market report in minutes
Epidemiology, competitive landscape, pipeline, KOL panel, regulatory, SWOT. A coordinated team of agents researches each dimension in parallel, cites its sources, and flags AI estimates so you know exactly what to trust.
- Real-time web intelligence with source citations on every KPI
- Citation badges: Verified / Estimated / AI estimate
- KPI cards with source URLs for every number
- Re-run any single agent without regenerating the full report
10
Specialized AI agents per report
<8 min
Average full report generation time
100%
Source cited for every data point
50+
Markets and indications supported
Report Structure
Every dimension of your market, covered automatically
Market Summary
Executive overview of market size, key dynamics, and opportunity sizing with verified data sources.
Market Sizing
Bottom-up and top-down market estimates. Patient population, treatment rates, revenue potential by geography.
Competitive Landscape
Current market leaders, market share breakdown, positioning analysis, and head-to-head comparisons.
Pipeline Intelligence
Clinical stage assets, expected launch timelines, mechanism of action, and threat assessment.
KOL Panel
Identified thought leaders ranked by h-index, publication volume, trial participation, and congress presence.
Regulatory
Approval status, label restrictions, reimbursement landscape, and upcoming regulatory milestones.
Treatment Landscape
Standard of care mapping, treatment algorithms, switching dynamics, and unmet needs analysis.
Epidemiology
Diagnosed and undiagnosed patient populations, incidence, prevalence, and patient journey insights.
SWOT
AI-synthesized strategic assessment across all report dimensions with actionable recommendations.
How It Works
From a single prompt to a board-ready report
01
Define your market
Enter your indication, geography, and target brand. pharcel pre-fills from your existing pipeline data if connected.
02
10 agents run in parallel
Each specialized agent searches the web, academic databases, and regulatory sources simultaneously. No sequential bottlenecks.
03
Review, trust, and act
Every KPI shows its source. Every AI estimate is flagged. Export to PDF or push directly to your CRM and BI tools.
See a live Market Intelligence report for your indication
Book a demo and we will run a real report live for any market you choose. No slides, no decks. Just pharcel working.
Request a Demo